Dynamic multidrug therapies for HIV: A control theoretic approach

Journal of Theoretical Biology

Volumn 185, Issue 1, 1997, Pages 15-29

  Wein, Lawrence M ^a   Zenios, Stefanos A ^b   Nowak, Martin A ^c  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b STANFORD UNIVERSITY   (United States)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ARTICLE; COMPUTER SIMULATION; DISEASE COURSE; DRUG CHOICE; DYNAMICS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MATHEMATICAL MODEL; PRIORITY JOURNAL; TREATMENT PLANNING; VIRUS MUTANT;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0031557385     PISSN: 00225193     EISSN: None     Source Type: Journal    
DOI: 10.1006/jtbi.1996.0253     Document Type: Article

References (44)

1. AGUR, Z. (1989). A new method for reducing cytotoxicity of the anti-AIDS drug AZT. In: Biomedical Modeling and Simulation (Levine, D. S., ed.) pp. 59-61. J. C. Baltzer AG, Scientific Publishing Co. IMACS.
2. BELLMAN, R. E. (1957). Dynamic Programming. Princeton NJ: Princeton University Press.
3. CARRIER, G. F. & PEARSON, C. E. (1991). Partial Differential Equatioins. San Diego, CA: Academic Press.
4. CONDRA, J. H. SCHLEIF, W. A., BLAHY O. M., GABRYELSKI, L. J., GRAHAM, D. J., QUINTERO A. R. et al. (1995). In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374, 569-571.
5. DE JONG, M. D., VEENSTRA, J., STILANAKIS, N. I., SCHUURMAN R., LANGE, J. M. A., DE BOER, R. J. et al. (1996). Host-parasite dynamics and outgrowth of virus containing a single K70R amino acid change in reverse transcriptase are responsible for the loss of HIV-1 RNA load suppression by zidovudine. Proc. Natl Acad. Sci. U.S.A. 93, 5501-5506.
6. ELLIOTT, R. J., AGGOUN, L. & MOORE, J. B. (1994). Hidden Markov Models: Estimation and Control. New York: Springer-Verlag.
7. EMBRETSON, J., ZUPANCIC, M., BENEKE, J., TILL M., WOLINSKI, S., RIBAS, J. L. et al. (1993). Analysis of human immunodeficiency virus-infected tissues by amplification and in situ hybridization reveals latent and permissive infections at single-cell resolution. Proc. Natl. Acad. Sci. U.S.A. 90, 357-361.
8. + cells per cubic millimeter. New Engl. J. Med. 333, 1662-1669.
9. FROST, S. D. W. & MCLEAN, A. R. (1994). Quasispecies dynamics and the emergence of drug resistance during zidovudine therapy of HIV infection. AIDS 8, 323-332.
10. GITTINS, J. C. (1989). Multi-armed Bandit Allocation Indices. New York: Wiley.
11. GOLUB, G. H. & VAN LOAN, C. F. (1989). Matrix Computations. Baltimore: Johns Hopkins University Press.
12. Ho, D. D., NEUMANN, A. U., PERELSON, A. S., CHEN, W., LEONARD, J. M. & MARKOWITZ, M. et al. (1995). Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373, 123-127.
13. HOWARD, R. A. (1960). Dynamic Programming and Markov Processes. Cambridge, MA: MIT Press.
14. KEY, P. B. (1990). Optimal control and trunk reservation in loss networks. Prob. Engrg. Inf. Sci. 4, 203-242.
15. KIRSCHNER, D. & PERELSON, A. (1994). A model for the immune system response to HIV: AZT treatment studies. In: Mathematical Populations Dynamics III, Theory of Epidemics (Arino, O., Axelrod, D. & Kimmel, M., eds.) vol. 1, pp. 296-301. Winnipeg Manitoba: Wuerz Publications.
16. KIRSCHNER, D. & WEBB, G. F. (1995). Effects of drug resistance in chemotherapy strategies in the treatment of HIV infection. Bull. Math. Biol. (in press).
17. KIRSCHNER, D. & WEBB, G. F. (1996). A model for treatment strategy in the chemotherapy of AIDS. Bull. Math. Biol. 58, 367-390.
18. KIRSCHNER, D., LENHART, S. & SERBIN, S. (1995). Optimal control of the chemotherapy of HIV. J. Math. Biol. (in press).
19. KOJIMA, E., SHIRASAKA T., ANDERSON B. D., CHOKEKIJCHAI S., STEINBERG S. M., BRODER S. et al. (1995). Human immunodeficiency virus type 1 (HIV-1) viremia changes and development of drug-related mutations in patients with symptomatic HIV-1 infection receiving alternating or simultaneous zidovudine and didanosine therapy. J. Infect. Dis. 171, 1152-1158.
20. LAGAKOS, S., PETTINELLI, C., STEIN, D. & VOLBERDING, P. A. (1993). The Concorde Trial. Lancet 341, 1276.
21. LARDER, B. A., KELLAM, P. & S. D. KEMP. (1993). Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro. Nature 365, 451-453.
22. LARDER, B. A., KEMP, S. D. & HARRIGAN, P. R. (1995). Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 269, 696-699.
23. MANSKY, L. M. & TEMIN, H. M. (1995). Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J. Virol. 69, 5087-5094.
24. MCLEAN, A. R. & NOWAK, M. A. (1992). Competition between zidovudine sensitive and zidovudine resistant strains of HIV. AIDS 6, 71-79.
25. MCLEOD, G. X. & HAMMER, S. M. (1992). Zidovudine: 5 years later. Ann. Int. Med. 117, 487-501.
26. NABEL, G. J. (1994). Gene therapy approaches to AIDS. AIDS 8, S61-S69.
27. NOWAK, M. A. & MAY, R. M. (1993). AIDS pathogenesis: mathematical models of HIV and SIV infections. AIDS 7, S3-S18.
28. NOWAK, M. A., ANDERSON, R. M., MCLEAN A. R., WOLFS, T. F. W., GOUDSMIT, J. & MAY, R. M. (1991). Antigenic diversity thresholds and the development of AIDS. Science 254, 963-969.
29. OTT, T. J. & KRISHNAN K. R. (1985). State dependent routing of telephone traffic and the use of separable routing schemes. In: Proceedings of the 11th International Teletraffic Congress (Akiyama, M., ed.). Amsterdam: Elsevier.
30. PANTALEO, G., COHEN, O. J., SCHWARTZENTRUBER D. J., GRAZIOSI C., VACCAREZZA M. & FAUCI A. S. (1995). Pathogenic insights from studies of lymphoid tissue from HIV-infected individuals. J. AIDS Hum. Retrovir. 10 (Suppl. 1), S6-S14.
31. PERELSON, A. S. (1989). Modeling the interaction of the immune system with HIV. In: Mathematical and Statistical Approaches to AIDS Epidemiology (Castillo-Chavez, C., ed.) Lecture Notes in Biomathematics, vol. 83, pp. 350-370.
32. + cells. Math. Biosci. 114, 81-125.
33. PERELSON, A. S., NEUMANN, A. U., MARKOWITZ, M., LEONARD, J. M. & HO, D. D. (1996). HIV-1 dynamics in vivo: Virion clearance rate, infected cell lifespan, and viral generation time. Science 271, 1582-1586.
34. PONTRYAGIN, L. S., BOLTYANSKII, V. G., GAMKRELIDZE, R. V. & MISHCHENKO, E. F. (1962). The Mathematical Theory of Optimal Progesses. New York: Interscience Publishers.
35. RICHMAN, D. D., MENG, T., SPECTOR, S. A., FISCHL, M. A., RESNICK, L. & LAI, S. (1994). Resistance to AZT and ddC during long-term combination therapy in patients with advanced infection with human immunodeficiency virus. J. AIDS 7, 135-138.
36. ST. CLAIR, M. H., MARTIN, J. L., TUDOR-WILLIAMS, G., BACH, M. C., VAVRO, C. L., KING, D. M. et al. (1991). Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 253, 1557-1559.
37. SCHUURMAN, R., NIJHUIS, M., VAN LEEUWEN R., SCHIPPER P., DE JONG, D., COLLIS, P., et al. (1995). Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J. Infect. Dis. 171, 1411-1419.
38. SCHWARTZ, D. H., SKOWRON, G. & MERIGAN, T. C. (1991). Safety and effects of interleukin-2 plus zidovudine in asymptomatic individuals infected with human immunodeficiency virus. J. AIDS 4, 11-23.
39. SHAFER, R. W., KOZAL, M. J., WINTERS, M. A., IVERSON, A. K. N., KATZENSTEIN, D. A., RAGNI M. V. et al. (1994). Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations. J. Infect. Dis. 169, 722-729.
40. SHAFER, R. W., IVERSON, A. K. N., WINTERS, M. A., AGUINIGA, E., KATZENSTEIN, D. A., MERIGAN, T. C. et al. (1995). Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. J. Infect. Dis. 172, 70-78.
41. VOLBERDING, P. A., LAGAKOS, S. W., GRIMES, J. M., STEIN, D. S., BALFOUR, J. J. REICHMAN, R. C. et al. (1994). The duration of zidovudine benefit in persons with asymptomatic HIV infection. JAMA 272, 437-442.
42. WEI, X., GHOSH, S. K., TAYLOR, M. E. JOHNSON, V. A., EMINI, E. A., DEUTSCH P. et al. (1995). Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373, 117-123.
43. WILSON, C. C. & HIRSCH, M. S. (1995). Combination antiretroviral therapy for the treatment of human immunodeficiency virus type-1 infection. Proc. Ass. Am. Phys. 107, 19-27.
44. WILSON, C. C., WONG, J. T., GIRARD, D. D. MERRILL, D. P., DYNAN, M., AN D. D. et al. (1995). Ex vivo expansion of CD4 lymphocytes from human immunodeficiency virus type 1-infected persons in the presence of combination antiretroviral therapy. J. Infect. Dis. 172, 88-96.